Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation
Orexigen Therapeutics, Inc. (OREXQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2017 8-K/A Quarterly results
10/17/2016 8-K/A Financial Statements and Exhibits
Docs: "Consent of KPMG LLP",
"Audited statement of assets acquired and liabilities assumed of Contrave as of March 31, 2016 and 2015, and the related audited statements of revenues and direct expenses for each of the years in the two-year period ended March 31, 2016, and the unaudited statement of assets acquired and liabilities assumed of Contrave as of June 30, 2016 and the related unaudited statements of revenues and direct expenses for the three months ended June 30, 2016 and 2015, and the related notes to the financial statements",
"Unaudited Pro Forma Condensed Combined Financial Statements"
11/03/2011 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 2 to Amended and Restated Employment Agreement between Mark Booth and the Company"
10/13/2011 8-K/A Submission of Matters to a Vote of Security Holders
04/29/2009 8-K/A Form 8-K/A -- Current report [amend]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy